Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Levemir er større end risiciene ved behandling af diabetes mellitus.
The Committee for Medicinal products for Human Use (CHMP) decided that Levemir’ s benefits are greater than its risks for the treatment of diabetes mellitus.